The Medical News

blogs

Winners of Promega UK’s 2019 Helix Sustainability Awards announced The combination of CRISPR-Cas9 and Promega protein reporters have proven powerful in understanding critical areas of biology. A paper in the journal ACS Chemical Biology explains how the Promega HiBiT Protein Tagging System can be combined with CRISPR-Cas9-mediated gene editing to tag endogenous proteins and simplify their study under natural expression conditions. Another paper also in ACS Chemical Biology explains a strategy for monitoring PROTAC-mediated degradation of endogenously tagged HiBiT-BET family members in live cells. Under this licensing agreement, Promega plans to use our intellectual property to develop CRISPR-edited cell lines, which can play a major role in determining drug efficacy , toxicity and overall development.” Udit Batra, CEO, MilliporeSigma MilliporeSigma intends to continue growing its CRISPR intellectual property portfolio with technologies such as paired Cas9 nickases, which reduce off-target effects, and proxy-CRISPR, which offers researchers more experimental options to accelerate drug development and access to new therapies. MilliporeSigma holds 22 CRISPR-related patents worldwide covering both methods and compositions, including the fundamental use of CRISPR-Cas9 for genetic integration in mammalian cells. Promega is building a portfolio of CRISPR knock-in cell lines, in addition to custom requests, to meet the demands of customers studying protein dynamics. Source: